US Stock MarketDetailed Quotes

BCRX BioCryst Pharmaceuticals

Watchlist

4.160
-0.050-1.19%

Close Apr 25 16:00 ET

4.170
+0.010+0.24%

Post 17:11 ET

857.58MMarket Cap-3525P/E (TTM)

BioCryst Pharmaceuticals Stock Forum

Jaguar8

Apr 17 16:32

$BioCryst Pharmaceuticals(BCRX.US)$
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

Trytosaveabit

Apr 10 19:14

Don’t put much into analyst’s targets, but!

$BioCryst Pharmaceuticals(BCRX.US)$ Still with the buy rating with a 12 PT!

Stock Region

Feb 24 07:01

American Biotech Company Presents Data That Treats Hereditary Angioedema

Unprecedented HAE Attack Rate Reductions with ORLADEYO® (berotralstat): A Breakthrough in Medical Science.
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...

Trytosaveabit

Feb 23 20:06

Update

$BioCryst Pharmaceuticals(BCRX.US)$ BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment

Trytosaveabit

Feb 19 22:16

News

$BioCryst Pharmaceuticals(BCRX.US)$ RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the fi...

LeroyFerguson

Feb 8 03:25

$BioCryst Pharmaceuticals(BCRX.US)$ agilon health is up

Trytosaveabit

Jan 25 06:35

Update/Blackrock!

$BioCryst Pharmaceuticals(BCRX.US)$ BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
SEC announcement· 1 min ago

Moomoo AI

Jan 24 01:31

Investors are concerned about the company's path to profitability. If growth slows, profitability will be delayed. The company's negative equity could be a warning, though these losses are usually only on paper.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

Moomoo AI

Dec 28, 2023 18:55

BioCryst Pharmaceuticals' low P/S ratio could be due to below-average future revenue growth. The future revenue might not justify a higher P/S, possibly straining a substantial share price increase. Some warning signs in its investment analysis are significant to consider.

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Share Price Is Matching Sentiment Around Its Revenues

Trytosaveabit

Nov 29, 2023 20:15

News

$BioCryst Pharmaceuticals(BCRX.US)$ BioCryst Reports Approval Of ORLADEYO (Berotralstat) By National Administration of Drugs, Foods, And Medical Devices (ANMAT) In Argentina

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall